Bioanalytical Method Development and Validation for the Determination of Vasopressin Receptor Antagonist Conivaptan in Mouse Plasma at NanoLevel and its Pharmacokinetic Application

Author(s): Haitham Alrabiah, Ahmed Bakheit, Sabray Attia, Gamal A.E. Mostafa*.

Journal Name: Current Analytical Chemistry

Volume 15 , Issue 5 , 2019

Submit Manuscript
Submit Proposal


Background: Conivaptan inhibits two of vasopressin receptor (vasopressin receptor V1a and V2). Conivaptan is used for the treatment of hyponatremia, and in some instances, for the treatment of the heart failure.

Methods: The present study aimed to develop a simple, sensitive, and accurate HPLC with ultraviolet detection for the assay of conivaptan (CON) in mouse plasma using bisoprolol as internal standard (IS). A precipitation procedure was used to extract CON and the IS from the mouse plasma. CON was chromatographically separated using a C18 analytical column at 25°C. The separation was carried out using a mixture of phosphate buffer (50 mM): acetonitrile (60: 40, v/v, pH 4.5) with a flow rate of 1.0 ml/min and detection was performed at 240 nm.

Results: The assay was validated according to the US Food and Drug (FDA) guidelines. The method demonstrated linearity over a concentration range of 150 - 2000 ng/ml (correlation coefficient: r 2 = 0.9985). The mean recovery of CON from the mouse plasma was 101.13%. All validation parameters for CON were within the acceptable range.

Conclusion: The investigated method has been shown to be suitable for estimating the CON in plasma samples, and this method is sensitive and highly selective, allowing the estimation of its concentrations up to the nano-scale. The suggested method was successfully used in a pharmacokinetic study of CON in mouse plasma.

Keywords: Conivaptan, vasopressin receptor, mouse plasma, HPLC, UV detection, pharmacokinetic.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [591 - 598]
Pages: 8
DOI: 10.2174/1573411014666180330160158
Price: $95